Danny Brody

Former VP, The Green Organic Dutchman

Danny Brody is the former Vice President of Investor Relations at The Green Organic Dutchman Holdings Ltd. (TGOD). Danny has more than ten years of experience in finance and holds a Chartered Investment Manager (CIM) designation from the Canadian Securities Institute (CSI).

Before leading TGOD to the most successful IPO in cannabis history, he was previously the Director of Investor Relations at Emblem Cannabis, and took the company public through a highly successful IPO.

Danny spent eight years in the brokerage industry, where he specialized in fundraising, building and maintaining client portfolios, financial advising, marketing, business development, structuring, advanced due diligence, lead generation, and database management before making the switch to the cannabis industry.

John Vardaman

General Counsel & Chief Compliance Officer at Simplifya/ Co-Author, The Cole Memo

John Vardaman, III, is the General Counsel and Chief Compliance Officer at Simplifya, a regulatory compliance software company based in Denver. John has 15 years of experience working as a senior government official on some of the most challenging issues facing the financial services industry. John was an Assistant Deputy Chief at the U.S. Department of Justice (DOJ), and served as Counsel to the Treasury Department. He played an instrumental role in devising the federal policy for enforcing the Bank Secrecy Act and anti-money laundering laws.

At the DOJ, he was actively involved in drafting the agency’s guidance regarding financial crimes related to state legalization of cannabis, and notably co-authored The Cole Memo. He was also instrumental in devising DOJ policy regarding the enforcement of laws governing the structuring of financial transactions.

Vardaman is a graduate of Vanderbilt University, and he earned his law degree from Georgetown University.

Dr. Avtar Dhillon

Executive Chairman, Emerald Health Therapeutics

Dr. Avtar Dhillon is the Executive Chairman of Emerald Health Therapeutics, Inc, Emerald Health Pharmaceuticals and Emerald Bioscience Inc.

Dr. Dhillon has more than 35 years of experience as a life science entrepreneur. As a founder/co-founder or lead investor in dozens of life science companies, he has raised more than $1 billion in public and private financings. As President and CEO of Inovio Pharmaceuticals Inc., Dr. Dhillon led a turnaround with multiple successful financings and licensing deals with Merck, Wyeth (now Pfizer) and Roche. Before joining Inovio, he was Vice President of MDS Capital Corp. (now Lumira Capital Corp.).

Dr. Dhillon now serves as an active board member and chairman for multiple life science and investment companies. Prior to his business career, Dr. Dhillon practiced family medicine. He has a BSc (Honors) in Human Physiology and an MD from the University of British Columbia.

Jenn Larry

President, CBD Strategy Group Inc.

Jenn Larry is Founder and President of CBD Strategy Group Inc., a commercial marketing, brand development, and business strategy firm helping cannabis brands thrive inside the box of regulation.

Over the past 20 years, Jenn has worked with national and international companies, across emerging and regulated sectors including: Music, Online Gambling, Pharmaceuticals, Tobacco, Payments, Technology, and Consumer Packaged Goods. Her previous experience as VP Strategy & Operations for Precision Communications and as Strategic Planner – Digital Development at Ogilvy & Mather has allowed her to successfully create and execute trade, consumer, investor, and business strategies in markets and categories that are in a state of disruption, and ban traditional marketing and branding. Ms. Larry is well known for her ability to forecast trends and leverage business intelligence to lead change across organizations.

With a full-time focus on cannabis, Ms. Larry spends her time working with a variety of businesses across the cannabis and hemp landscape. Jenn helps commercial and not-for-profit companies navigate compliance and regulations helping to drive brand-to-market and route-to-market strategies. Jenn has spoken at over two dozen cannabis and hemp conferences and hosts her own events across Canada. Additionally, Jenn continues to work with media across North America and Europe to help educate the market on the legal requirements to operate successfully in the new world of cannabis. Currently Ms. Larry is a mentor at Growtech Labs.

Dr. Michael Dor

Senior Medical Advisor, Israel Ministry of Health

Dr. Michael Dor is the Senior Medical Advisor at the Israeli Ministry of Health’s Medical Cannabis Unit. Dr. Dor has collaborated extensively with Israeli organic chemist Raphael Mechoulam, who is known as the “father of cannabis research” for his contributions to the field.

Dr. Dor has also served as the Head of the Hospitals Division and Deputy Director of the Health Management in the ministry, where he initiated the quality control and licensing process of the Hospitals and the Clinical services in Israel. He voluntarily started a clinic for uninsured refugees and a shelter for victims of human trafficking, for which he was awarded the Presidential Award in 2014 – the highest civilian honor in Israel.

After retiring from the Ministry, Dr. Dor took up his role with the Medical Cannabis Unit, where he’s introduced more indications and helped improve the process of approval for treatments. He’s also continued his work as a family physician, and teaches at Ariel University and Hadassah College as a senior lecturer. Dr. Dor graduated from Tel Aviv University and earned a Master’s degree from Harvard University’s Kennedy School of Government. He continues to work as a practicing physician.

Tom Gentile

Cannabis Options Expert

Tom is one of the world’s foremost authorities on stock, futures, and options trading. With more than 25 years’ experience in the securities industry, Tom’s style of trading systems and strategies is designed to help individual investors propel themselves past 99% of the trading crowd, into the 1 Percent of highly successful investors. Since 2009, Tom has taught more than 300,000 traders the specific secrets of spotting high-probability and low-risk trade opportunities, and now he is going to use his years of options experience to bring the same explosive moneymaking power to the cannabis industry.

For the last decade, Tom Gentile has been an angel investor and entrepreneur in the medical marijuana industry. He owns a seed-to-product farm as well as other links in the cannabis supply chain. And by December 31, he’ll have the licensing necessary for a complete seed-to-product, farm-to-dispensary cannabis company.

Tom is the author and co-author of over a half-dozen books, including The Options Course, The Volatility Course, The Index Course, and The Stock Market Course, each of which is accompanied by a hands-on practice workbook. Tom has appeared on financial programs featured on CNBC’s U.S., Europe, and Asia Squawk Box, Bloomberg, Reuters, and Fox Business with Neil Cavuto, and is a contributing columnist to Stocks and Commodities Magazine. Tom is also contributor to Money Morning and writes regularly about cannabis investing in Power Profit Trades, the Fast Fortune Club, Money Calendar, Weekly Money Call, Alpha-9 Trader, and more.

D.R. Barton, Jr.

Cannabis Technical Trading Expert
D.R. Barton, Jr. is one of the most widely read financial coaches and a world-renowned authority on technical trading with 30 years of experience.
He is a regular analyst on Fox Business, CNBC, and Bloomberg Radio, and he has been featured on China Central Television America, BNN, MarketWatch, Financial Advisor magazine, SmartMoney, and the Van Tharp Institute.

D.R. also co-authored the New York Times and Wall Street Journal bestselling book Safe Strategies for Financial Freedom, a comprehensive guide for aggressively shedding risk without derailing profits.

D.R. is thrilled to bring his renowned strategy and system – which has helped hundreds of thousands master a new way of trading that focuses on market anomalies D.R. calls “extremes” – to the burgeoning cannabis sector.

The best part is, it works in any market or stock movement – bull, bear, or sideways.

D.R. holds a B.S. in Chemical Engineering from Virginia Tech and an MBA from the University of Delaware.

Michael A. Robinson

Director of Venture Capital and Technology Research, Money Morning

Michael A. Robinson is a 35-year Silicon Valley veteran and one of the top technology financial analysts working today. Michael is a consultant, senior adviser, and board member for Silicon Valley venture capital firms. He was one of five people involved in early meetings for the $160 billion “cloud” computing phenomenon, and was with Dave DeWalt, CEO of McAfee, right before Intel acquired his company for $7.8 billion.

Michael is a regular guest and panelist on CNBC and Fox Business. He’s also a Pulitzer Prize-nominated writer and reporter. Michael is a contributor to Money Morning and writers regularly about cannabis industry investing in Strategic Tech Investor, the Nova-X Report and Radical Technology Profits publications. He’s also worked for The New York Times and The Wall Street Journal.

Ernie Tremblay 

Biotech Investing Specialist, Money Morning

Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies. As a health editor and writer, Ernie has contributed to more than 100 publications on topics like diabetes, Alzheimer’s disease, arthritis, dermatology, and groundbreaking medical therapies for publishers like Prentice Hall, Harper Collins, and others. Through the years, he’s gained “insider” access to some of the world’s top medical professionals, including Nobel-caliber doctors the Yale School of Medicine’s Dr. Karel Liem, Jr., and Harvard Medical School’s Dr. William S. Beck.

Ernie contributes to Money Morning, and writes about biotech investing in his Biotech Insider Alert. He has a thorough understanding of the Food and Drug Administration (FDA) approval process, as well as the “hard science” behind new, experimental drugs and the market demand for them.

John Burke

Investigative Journalist

During his 25 years as an investigative journalist, John Burke joined James Cameron on a submarine journey that took him 2.5 miles beneath the ocean’s surface to explore the 1912 wreck of the Titanic. He’s uncovered new clues from the remote Nevada sites where the original atomic bomb tests were conducted. He’s travelled to the Great Basin searching for the origins of indigenous cultures that existed over 10,000 years ago. Each of these events had a profound effect on history… on cultures… on economies. Now, he’s taking on the American cannabis industry.

Joshua Sanderlin

Principal, Sanderlin Strategies, PLLC

Joshua Sanderlin is an attorney and government affairs expert with over 15 years of experience in regulatory law and public policy. He has worked in both state and federal government and has extensive experience advocating for clients before all three branches of the federal government.

Throughout his career, Joshua has represented clients including Fortune 100 companies, major U.S. municipalities, and foreign governments. His work on behalf of clients has exposed him to many complex issues that, like cannabis, go to the very heart of American federalism. He has also served as counsel to cannabis companies and start-ups facing varied challenges related to licensing, finance, and corporate governance.

As part of his commitment to driving the cannabis industry forward, Joshua has been an active member of the Congressional Cannabis Working Group and the International Cannabis Bar Association and has addressed evolving issues of cannabis policy at law schools and industry conferences. He has been quoted in major publications such as the Washington Post, Washington Examiner, and Chicago Tribute.

Joshua completed his B.A. at Jacksonville University, M.P.A. at Florida State University, and J.D. at the Catholic University of America.